

HEART DISEASE

Forensic Phytochemical Dossier

PI: Marie-Soleil Seshat Landry	DATE: April 12, 2026	MS-ID: MLS-2026-X	LHFP-DTRM-2026-MGUZN1IHQZ
--------------------------------	----------------------	-------------------	---------------------------

INSTITUTIONAL AFFILIATION: Independent Bioinformatics & Molecular Pathology Directorate, Canada

THIRD-PARTY DISCLOSURE: Predictive pharmacodynamic modeling, target mapping, and stoichiometric deconvolution facilitated by *in silico* heuristic computational engines.

■ CRITICAL DISCLAIMER — EPISTEMIC SANCTITY

FOR RESEARCH ONLY. POWERED BY PHYTOINTELLIGENCE. The molecular interactions, pharmacokinetic vectors, and biochemical matrices detailed herein represent theoretical, high-fidelity computational models mapping phytochemical compounds to cardiovascular pathological mechanisms. This manuscript strictly defines theoretical paradigms and structural interactions. It is categorically **NOT** intended for diagnostic interpretation, clinical intervention, or therapeutic extrapolation without rigorous *in vitro* assay validation and *in vivo* clinical trials. Epistemic sanctity dictates a strict demarcation between theoretical docking projections and biological implementation.

ABSTRACT — HYPOTHESIS SUMMARY

The progressive deterioration of myocardial and vascular tissues in heart disease is fundamentally driven by multi-axis dysregulation involving lipid accumulation, endothelial dysfunction, matrix degradation, and maladaptive hypertrophy. This manuscript proposes the **"Surgical Patch" hypothesis**: the deployment of a tightly calibrated polypharmacological matrix consisting of specific phytochemical agents designed to concurrently arrest distinct nodes of the cardiovascular pathological cascade. By synchronously modulating endothelial nitric oxide synthase (eNOS), inhibiting angiotensin-converting enzyme (ACE), antagonising Matrix metalloproteinase-9 (MMP-9), and suppressing p300 histone acetyltransferase (HAT) and HMG-CoA reductase pathways, the proposed combinatorial molecular "patch" aims to theoretically reconstruct vascular architecture, stabilise atheromatous plaques, and attenuate ventricular remodelling.

INTRODUCTION: PATHOLOGY DECONVOLUTION

Heart disease manifests as an intricate nexus of mechanical, biochemical, and hemodynamic dysregulations. Atherogenesis is initiated by the subendothelial retention of apolipoprotein B-containing lipoproteins, triggering localised inflammatory cascades. This induces the focal formation of reactive oxygen species (ROS), which rapidly quench basal nitric oxide, leading to profound endothelial dysfunction. Concurrently, macrophage phenotypic switching and uninhibited lipid engulfment result in foam cell accumulation, forming the necrotic core of atheromatous plaques.

Compounding these vascular defects, systemic hypertension exerts maladaptive mechanical shear stress, stimulating vascular smooth muscle cell proliferation and upregulating ACE pathways. As arterial compliance diminishes, the myocardium undergoes pathological hypertrophy via epigenetic reprogramming—specifically driven by histone acetyltransferases (e.g., p300 HAT) and NF-κB signalling—ultimately precipitating heart failure. To effectively intercept this multi-nodal pathology, a singular monotherapy is structurally insufficient; a multi-target combinatorial matrix is theoretically necessitated.

BIOCHEMICAL INTERACTION TOPOLOGY




Figure 1. Multi-node cardiovascular pathological cascade targeted by the Surgical Patch phytochemical matrix. Arrows indicate mechanistic interventions at discrete molecular nodes.

PHARMACODYNAMIC MODELING: DOCKING & MECHANISM

1. Resveratrol (*Stilbenoid phyto-compound*)

Identification:	PubChem CID 445154 CAS: 501-36-0
Molecular Constants:	MW: 228.24 g/mol XLogP3: 3.1
Primary Target:	SIRT1 — NAD-dependent protein deacetylase sirtuin-1 [UniProt: Q96EB6]
Mechanism:	Direct allosteric activator of SIRT1. Lowers activation energy for SIRT1-mediated deacetylation, inducing eNOS upregulation. Demonstrates high binding affinity inhibiting vascular smooth muscle cell proliferation.
Pathological Vector:	Cardioprotective baseline against ischaemia-reperfusion injury and atherosclerosis. [PMID: 26799041]

2. Quercetin (*Plant flavonol*)

Identification:	PubChem CID 5280343 CAS: 117-39-5
Molecular Constants:	MW: 302.23 g/mol XLogP3: 1.5
Primary Target:	ACE — Angiotensin-converting enzyme [UniProt: P12821]
Mechanism:	Potent competitive inhibition (IC50 profile) within the ACE metallopeptidase active site.
Pathological Vector:	Natural antihypertensive pathway modulator. Modulates oxidative stress and reverses endothelial dysfunction in atherogenesis.

3. Epigallocatechin Gallate (EGCG) (*Green tea catechin*)

Identification:	PubChem CID 65064 CAS: 989-51-5
Molecular Constants:	MW: 458.37 g/mol XLogP3: 1.1
Primary Target:	MMP-9 — Matrix metalloproteinase-9 [UniProt: P14780]
Mechanism:	Potent inhibition via rigorous hydrogen bonding at the catalytic zinc ion cleft of MMP-9.
Pathological Vector:	Prevents extracellular matrix degradation and plaque rupture. Validated in vivo for anti-atherosclerotic efficacy. [PMID: 17906191]

4. Curcumin (*Diarylheptanoid*)

Identification:	PubChem CID 969516 CAS: 458-37-7
Molecular Constants:	MW: 368.38 g/mol XLogP3: 3.2
Primary Target:	p300 HAT / NF-κB p65 [UniProt: Q04206]
Mechanism:	Targeted allosteric inhibition, repressing acetylation necessary for pathogenic gene transcription.
Pathological Vector:	Attenuates maladaptive cardiac hypertrophy and heart failure progression by downregulating inflammatory and hypertrophic gene expressions.

5. Allicin (*Organosulfur compound*)

Identification:	PubChem CID 65036 CAS: 539-86-6
Molecular Constants:	MW: 162.27 g/mol XLogP3: 1.3
Primary Target:	HMG-CoA reductase [UniProt: P04035]
Mechanism:	Direct enzymatic inhibition on the mevalonate pathway.
Pathological Vector:	Hypercholesterolaemia reduction; lowers systemic apolipoprotein B burdens, depriving the atherogenic cascade of its primary substrate.

To maintain epistemic validity, the "Surgical Patch" polypharmacological hypothesis must be strictly falsifiable. We define the aggregated biological response metric to the theoretical treatment matrix M_{tx} as $\mu(M_{tx})$, mapped against a placebo baseline control $\mu(P_{\blacksquare})$.

Null Hypothesis ($H_{\blacksquare}$):

The application of the defined molecular constants yields no statistically significant cardioprotective or structural remodelling effects:

$$H_0 : \mu(M_{tx}) - \mu(P_0) \leq 0$$

To explicitly reject $H_{\blacksquare}$, the empirical model must achieve the alternative hypothesis (H_a) across three isolated biometric axes, surpassing the clinically significant threshold δ :

$$H_a : \Delta\mu(M_{tx}) > \delta$$

where $\Delta\mu$ is determined by the discrete integration of the following continuous parameters over time t :

1. Vascular Hemodynamics $V_h(t)$:

$$V_h(t) = \int_0^t \left(\frac{\partial(eNOS_{up})}{\partial t} + \frac{\partial(ACE_{inh})}{\partial t} \right) dt$$

2. Structural Plaque Volume $S_p(t)$:

$$S_p(t) = \frac{d}{dt} [FoamCell_{vol}] \propto - [MMP9_{inh}]$$

3. Hypertrophic Index H_i :

$$H_i = \lim_{t \rightarrow \infty} \left(\frac{LV\ Mass_{tx}}{LV\ Mass_{control}} \right) < 1.0$$

Failure to observe reduction in serum atherogenic lipids (via HMG-CoA reductase suppression), failure to arrest ventricular mass scaling (via p300 HAT inhibition), or failure to stabilise ECM integrity (via MMP-9 antagonism) at an $\alpha = 0.05$ significance level will mandate retention of $H_{\blacksquare}$, indicating the theoretical multi-target synergy fails translation to *in vitro* and *in vivo* efficacy.

FORMAL REFERENCES

1. CAS Registry / PubChem Golden Record. Compound Data: Resveratrol (CAS: 501-36-0), Quercetin (CAS: 117-39-5), EGCG (CAS: 989-51-5), Curcumin (CAS: 458-37-7), Allicin (CAS: 539-86-6). National Center for Biotechnology Information, 2026.
2. UniProt Consortium. Primary Protein Targets: SIRT1 [Q96EB6], ACE [P12821], MMP-9 [P14780], p300 HAT/NF- κ B p65 [Q04206], HMG-CoA reductase [P04035]. UniProt Knowledge Base, 2026.
3. NIH / PubMed. PMID: 26799041. Carrizzo A et al. "Resveratrol and cardiovascular diseases." *Nutrition, Metabolism and Cardiovascular Diseases*, 2016.
4. NIH / PubMed. PMID: 17906191. Cabrera C et al. "Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications." *Food and Chemical Toxicology*, 2006.